All Access Articles |
- Regenxbio Doses First Patient in Phase IIb/III Diabetic Retinopathy Trial | 2026-06-29 | BIOTECHNOLOGY
- Regenxbio Reports $170.4M Revenue in 2025 | 2026-03-05 | UNITED STATES
- Regenxbio FDA Review Timeline Extended | 2025-08-19 | BIOTECHNOLOGY
- Regenxbio Appoints Mitchell Chan as CFO | 2024-09-18 | BIOTECHNOLOGY